Samvveda S. Sameel

An Unusual Presentation of Brucellosis, Involving Multi-organ Systems: A Case Report

Ranjana Kaintura, Sonika Agarwal, A. A. Vaidya, Samvveda S. Sameel

Real world use of dalbavancin for bone and joint infections: a retrospective case series in adults and children

Preeti S. Ajapuje, Samvveda S. Sameel, Dipti Gaikwad, Pramod S. Kumar et autres

BACKGROUND: Bone and joint infections (BJIs) often require prolonged parenteral therapy, with challenges of hospitalization and vascular access [1–4]. Dalbavancin, a long-acting lipoglycopeptide, enables once-weekly dosing [7–10]. This study reports real-world outcomes of dalbavancin, used off-label in adults and children with BJIs. …

in (code pays fourni par la source)

Molecular Alarm, Phenotypic Calm: A Rare Case of rpoB 511CCG Mutation in Tuberculosis with Review of Literature

Preeti S. Ajapuje, Jaikumar D. Mulchandani, Dipti Gaikwad, Samvveda S. Sameel

Abstract Background: Rapid molecular diagnostics like GeneXpert Mycobacterium tuberculosis /RIF-Ultra are pillars of tuberculosis (TB) care but can detect “disputed” rpoB mutations, which confer low-level rifampicin resistance (RR) often missed by phenotypic drug susceptibility testing (DST). This genotypic–phenotypic discordance creates significant therapeutic …

in (code pays fourni par la source)

Comparative evaluation of intrathecal isobaric levobupivacaine 0.5% and isobaric ropivacaine 0.5% in transurethral resection of prostate surgeries – a randomized control trial

Swati Bhau, Vanilla Chopra, Parul Gohil, Samvveda S. Sameel

Background: Isobaric levobupivacaine and ropivacaine are newer long-acting local anesthetics that offer a favorable safety profile compared to bupivacaine, making them valuable alternatives for spinal anesthesia, particularly in elderly patients undergoing transurethral resection of the prostate (TURP). Aims and Objectives: This study …

in (code pays fourni par la source)

The Reset-α Study: A Double Blind, Randomized, Multi Centre, Phase III Trial for the Efficacy and Safety of Thymosin α-1 (Tα1) in Sepsis Patients

Samvveda S. Sameel, Dhruva Chaudhry, Ganshyam M. Jagathkar, Amrita Gupta et autres

Aims and Background: Thymosin alpha 1 (Tα1) has shown promise as an adjuvant treatment for sepsis. This study evaluated the efficacy and safety of Tα1 versus placebo, both combined with standard care, in patients with sepsis. Methods: This was a multicenter, randomized, …

in, Afrique du Sud (code pays fourni par la source)